Recently, multiple ICPs are investigated as novel targets in experimental tumor models or in clinical trials, like LAG3, TIM-3, TIGIT, BTLA and/or agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS (93). Here, HAVCR2 is linked to neoplasm.